Tianda Pharmaceuticals Limited

455 KYG887471038

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
0.265 ^HKD	+3.92%		+1.92%	+21.56%

Mar. 26	Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 28 June 2024	CI
Mar. 26	Tianda Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tianda Pharmaceuticals Limited Approves Final Dividend

June 27, 2023 at 05:08 am EDT

Tianda Pharmaceuticals Limited at its AGM held on June 27, 2023 approved final dividend of 0.26 Hong Kong cents per share.

Latest news about Tianda Pharmaceuticals Limited

Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 28 June 2024	Mar. 26	CI
Tianda Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Current Year from 1 January 2023 to 31 December 2023	Mar. 21	CI
Tianda Pharmaceuticals Limited Announces Executive Changes, Effective 29 August 2023	23-08-28	CI
Tianda Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Tianda Pharmaceuticals to Shrink H1 Loss by Over 70%	23-08-24	MT
Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Interim Period Ended June 30, 2023	23-08-23	CI
Tianda Unit Buys Out 45% Stake in Meng Sheng Pharmaceutical	23-08-02	MT
Tianda Pharmaceuticals Limited entered into an equity transfer agreement to acquire 45% stake in Yunnan Mengsheng Pharmaceutical Co., Ltd from Yunnan Linuo Biotechnology Co., Ltd. for HKD 23.5 million.	23-07-31	CI
Tianda Pharmaceuticals Limited Announces Board Changes	23-06-27	CI
Tianda Pharmaceuticals Limited Approves Final Dividend	23-06-27	CI
Tianda Pharmaceuticals Limited Proposes Final Dividend for the Nine Months Ended 31 December 2022, Payable on or Before, 14 July 2023	23-05-19	CI
Tianda Pharmaceuticals Unit to Invest HK$10 Million in Fund	23-04-19	MT
Beijing Tong Ren Tang Chinese Medicine’s CEO Redesignated; New CEO Named	23-04-19	MT
Tianda Pharmaceuticals Limited Announces Final Ordinary Dividend for the Nine Months Ended 31 December 2023	23-03-23	CI
Tianda Pharmaceuticals Limited Reports Earnings Results for the Nine Months Ended December 31, 2022	23-03-23	CI
Tianda Pharmaceuticals Limited Reports Earnings Results for the Nine Months Ended December 31, 2022	23-03-23	CI
Tianda Pharmaceuticals Warns of Higher Loss in Fiscal Nine-Month Period; Shares Tumble 9%	23-03-20	MT
Tianda Pharmaceuticals Limited Provides Group Earnings Guidance for the Nine Months Period from April 1, 2022 to December 31, 2022	23-03-19	CI
Tianda Pharmaceuticals to Set Up Additional Production Line to Meet Rising Medicine Demand	22-12-19	MT
Tianda Pharmaceuticals' Loss for Half Year Through September Narrows	22-11-27	MT
Tianda Pharmaceuticals Limited Announces Changes in Financial Year End Date	22-11-25	CI
Tianda Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2022	22-11-25	CI
Tianda Pharmaceuticals Chairman Buys 1.9 Million Shares; Stock Rises 3%	22-10-28	MT
Tianda Pharmaceuticals Limited Declares Final Dividend	22-08-31	CI

Chart Tianda Pharmaceuticals Limited

Duration

Period

More charts

Tianda Pharmaceuticals Limited is a Hong Kong-based investment holding company principally engaged in pharmaceutical businesses. The main businesses of the Company include the research and development, production and sales of pharmaceutical, biotechnology and healthcare products. Its products include cardio-cerebrovascular drugs, paediatric drugs, anti-flu and respiratory system drugs, anti-infection drugs, medicines for drug addicts and other pharmaceutical products, as well as healthcare products under the Herb Valley series. The Company operates businesses in Hong Kong, China and Australia.

Sector

Pharmaceuticals

Calendar

2024-06-25 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TIANDA PHARMACEUTICALS LIMITED	+21.56%	72.78M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B